Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
October 2012, Vol 3, No 7
October 2012, Vol 3, No 7
Head-to-Head Comparison: Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
By
Caroline Helwick
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—In a head-to-head comparison of 2 treatments for metastatic renal-cell carcinoma (mRCC), pazopanib (Votrient) showed similar efficacy to sunitinib (Sutent), with a 1-month survival advantage for sunitinib, which was associated with fewer side effects and an increased quality of life (QOL), suggested Robert J. Motzer, MD, Professor of Medicine, Weill Medical College of Cornell University, and an attending physician at Memorial Sloan-Kettering Cancer Center, New York.
Read Article
High Economic Burden Associated with Thromboembolism in Patients with Cancer
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
A review of 34,000 patients with cancer in an insurance claims database showed that during the first 12 months after the diagnosis of cancer, the overall cost of developing venous thromboembolism (VTE) was approximately $100,000 per patient, reported Duke University researchers at the 2012 European Society for Medical Oncology.
Read Article
New Drugs for the Treatment of Prostate Cancer
By
Phoebe Starr
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—Promising preliminary results for 2 novel prostate can-cer drugs—ODM-201 and OGX-427—were reported at the 2012 European Society for Medical Oncology Congress. Both drugs were studied for the treatment of castration-resistant prostate cancer (CRPC).
Read Article
Soy Isoflavone Intake Significantly Reduces Risk of Breast Cancer Recurrence, May Improve Survival
In the Literature
October 2012, Vol 3, No 7
It has been suggested in previous studies that soy isoflavones have anticancer properties; however, it is also known that soy-based foods possess estrogen-like properties and can therefore present complications rather than benefits for patients with breast cancer, potentially even playing a role in the genesis of breast cancer or its progression. Now 2 new studies indicate that daily consumption of soy-based foods may confer benefits for patients with breast cancer.
Read Article
Adding Cetuximab to Chemotherapy Improves Outcomes in Patients with KRAS G13D Mutation
In the Literature
October 2012, Vol 3, No 7
A recent analysis of previously published data indicates that adding cetuximab to first-line therapy benefits patients with the
KRAS
G13D mutation (Tejpar S, et al.
J Clin Oncol
. 2012;30:3570-3577).
Read Article
Enzalutamide Prolongs Overall Survival after Chemotherapy in Prostate Cancer
In the Literature
October 2012, Vol 3, No 7
In this phase 3, double-blind, placebo-controlled clinical trial, enzalutamide significantly prolonged survival in patients with castration-resistant prostate cancer (CRPC) after standard chemotherapy (Scher HI, et al.
N Engl J Med
. 2012;367:1187-1197).
Read Article
Marqibo New Option for Acute Lymphoblastic Leukemia
FDA Approvals, News & Updates
October 2012, Vol 3, No 7
The FDA accelerated the approval of vincristine sulfate liposome injection (Marqibo; Talon Therapeutics) for the treatment of patients with Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL), a rare type of leukemia, with a second or greater relapse after treatment with ≥2 antileukemia therapies. The drug is designated as an orphan product.
Read Article
FDA Approves Neutroval for Severe Neutropenia
FDA Approvals, News & Updates
October 2012, Vol 3, No 7
The FDA approved tbo-filgrastim (Neutroval; Sicor Biotech UAB, a member of Teva Corporation) to reduce the duration of severe neutropenia in patients with cancer receiving chemotherapy.
Read Article
Regorafenib Latest Therapy Approved for Metastatic Colorectal Cancer
FDA Approvals, News & Updates
October 2012, Vol 3, No 7
Using its priority review process, the US Food and Drug Administration (FDA) approved the oral multikinase inhibitor regorafenib (Stivarga; Bayer HealthCare Pharmaceuticals) for the treatment of patients with metastatic colorectal cancer (mCRC).
Read Article
Indirect Costs of Metastatic Breast Cancer Are Substantial
By
Caroline Helwick
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—The indirect costs of metastatic breast cancer are substantial and are much higher than the costs of early breast cancer, according to what may be the first study to compare costs related to lost productivity in the population with breast cancer.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma